| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-09-30 | brodalumab (AMG 827) | psoriasis | 3 | Amgen (USA - CA) AstraZeneca (UK) | Autoimmune diseases - Dermatological diseases |
| 2015-09-30 | TEV-48125 (formerly LBR-101/ RN-307) | migraine | 2b | Teva Pharmaceutical Industries (Israel) | CNS diseases |
| 2015-09-30 | brodalumab (AMG 827) | psoriasis | 3 | Amgen (USA - CA) AstraZeneca (UK) | Autoimmune diseases - Dermatological diseases |
| 2015-09-29 | CAD106 and CNP520 | Alzheimer's disease | 2-3 | Novartis Pharmaceuticals (Switzerland) Banner Alzheimer\'s Institute (USA - Denmark) National Institute on Aging (NIA) (USA) Alzheimer\'s Association (USA) | Neurodegenerative diseases |
| 2015-09-29 | PV-10 | preclinical | Provectus Pharmaceuticals (USA - TN) | Cancer - Oncology | |
| 2015-09-29 | mesenchymal precursor cells (MPCs) | end-stage or class IV New York Heart Association (NYHA) heart failure | 2 | Mesoblast (Australia) | Cardiovascular diseases |
| 2015-09-28 | house dust mite SLIT-tablet/Miticure™ | house dust mite allergy | Torii Pharmaceutical (Japan) | Allergic diseases - Immunological diseases - Respiratory diseases | |
| 2015-09-28 | ozanimod - RPC1063 | multiple sclerosis | 3 | Celgene (USA - NJ) | Autoimmune diseases - Neurodegenerative diseases |
| 2015-09-28 | custirsen | metastatic castrate-resistant prostate cancer | 3 | OncoGenex Pharmaceuticals (USA - WA) | Cancer - Oncology |
| 2015-09-28 | CHEMOSAT® Delivery System | liver metastases from ocular melanoma | Delcath Systems (USA - NY) | Cancer - Oncology | |
| 2015-09-28 | IPH2201 (anti-NKG2A antibody) | ovarian Cancer, Fallopian tube cancer, peritoneal cancer | 1-2 | NCIC Clinical Trials Group (Canada) Innate Pharma (France) | Cancer - Oncology |
| 2015-09-28 | ALLOB® | failed spinal fusion | 2a | Bone Therapeutics (Belgium) | Bone diseases - Regenerative medicine |
| 2015-09-27 | lenvatinib | thyroid cancer | 3 | Eisai (Japan) | Cancer - Oncology |
| 2015-09-27 | atezolizumab (MPDL3280A) | locally advanced or metastatic urothelial bladder cancer (UBC) that had progressed on initial treatment | 2 | Roche (Switzerland) | Cancer - Oncology |
| 2015-09-27 | Opdivo® (nivolumab) | non-squamous non-small cell lung cancer (NSCLC) | 3 | BMS (USA - NY) | Cancer - Oncology |
| 2015-09-26 | Xtandi® (enzalutamide) | advanced, androgen receptor (AR)-positive, triple-negative breast cancer (TNBC) | 2 | Medivation (USA - CA) Astellas (Japan) | Cancer - Oncology |
| 2015-09-25 | GLPG0634 (filgotinib) | rheumatoid arthritis | 2b | Galapagos (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2015-09-25 | pembrolizumab (MK-3475) | oesophageal carcinoma, oesophagogastric junction carcinoma | 3 | Merck&Co (USA - NJ) | Cancer - Oncology |
| 2015-09-25 | Opdivo® (nivolumab) | advanced or metastatic (medically or surgically unresectable) clear-cell renal cell carcinoma | 3 | BMS (USA - NY) Ono Pharmaceutical (Japan) | Cancer - Oncology |
| 2015-09-24 | talacotuzumab (JNJ-56022473) | acute myeloid leukemia (AML) | 2 | Janssen Biotech, a J&J company (USA - NJ) | Cancer - Oncology |
